Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gain Therapeutics, Inc.GANX · Entity 6943 | Chief Financial Officer | March 23, 2023 | March 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gain Therapeutics, Inc.
Report date March 23, 2023 · Filed March 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2033-03-23 | Direct | 50,000 |
Reported balance
After 2023-03-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-23 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares underlying the option shall vest 25% on March 23, 2024 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,000 |
Reported balance
After 2023-03-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-23 · Grant · Acquired 25,000 · Balance 25,000 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3: The RSUs shall vest 25% on March 23, 2024 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest 25% on March 23, 2024 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F3: The RSUs shall vest 25% on March 23, 2024 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2023 Filed Mar 27, 2023 21:28 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021260 · doc4.xml · derivative · entry 2 Calabrese Salvatore · CIK 0001851958 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs shall vest 25% on March 23, 2024 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs shall vest 25% on March 23, 2024 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 21:28 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001209191-23-021260 · doc4.xml · derivative · entry 1 Calabrese Salvatore · CIK 0001851958 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-23 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on March 23, 2024 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:37 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantRestricted Stock Units · Derivative | 9,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042572 · doc4.xml · derivative · entry 2 Calabrese Salvatore · CIK 0001851958 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 9,900 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs shall vest 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs shall vest 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:37 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 59,400 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001209191-22-042572 · doc4.xml · derivative · entry 1 Calabrese Salvatore · CIK 0001851958 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,400 Underlying: Common Stock · 59,400 shares Expires 2032-07-15 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on July 1, 2023 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 19, 2022 Filed May 19, 2022 21:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | PurchaseCommon Stock | 3,000 | $8,100.00 | $24,300,000.00 |
DisclosureSEC source: 0001415889-22-005317 · form4-05192022_050501.xml · nonDerivative · entry 1 Calabrese Salvatore · CIK 0001851958 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:00 UTC Amendment | Gain Therapeutics, Inc. GANX · Entity 6943 | PurchaseCommon Stock | 3,000 | $2.70 | $8,100.00 |
DisclosureSEC source: 0001415889-22-005491 · form4a-05232022_040535.xml · nonDerivative · entry 1 Calabrese Salvatore · CIK 0001851958 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.